RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Inc. (AMEX:ISR) a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the second quarter of fiscal year 2010, ended December 31, 2009.
